Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, Bendamustine, Bortezomib, and Lenalidomide in Previously Untreated Older Patients With Mantle Cell Lymphoma
NCT01415752Phase 2Active, not recruiting
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Aug 2012
- Primary completion
- Feb 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of bortezomib, lenalidomide in mantle cell lymphoma (MCL), sponsored by Eastern Cooperative Oncology Group. Started Aug 2012; status: active, not recruiting.
02
Drugs
bortezomiblenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01415752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01415752.